欢迎来到天天文库
浏览记录
ID:55057630
大小:211.09 KB
页数:3页
时间:2020-05-08
《恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析-论文.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、·3972·中华医院感染学杂志2014年第24卷第16期ChinJNosocomiolVo1.24No.162014doi:10.11816/cn.ni.2014—133739论著恩替卡韦治疗慢性乙型肝炎病毒感染患者临床疗效分析姜波,李忠,张宇(凯里市黔东南州人民医院感染科,贵州凯里556ooo)摘要:目的探讨并分析恩替卡韦治疗慢性乙型肝炎病毒感染患者的临床疗效和安全性,为临床治疗提供参考依据。方法选取医院自2011年1月一2012年6月收治的160例慢性乙型肝炎患者为研究对象,应用随机数字表法将慢性乙型肝炎病毒感染患者分为对照组和观察组,各8O例;观察组
2、患者口服恩替卡韦分散片0.5mg/d;对照组患者口服阿德福韦酯片10mg/d,疗程均为48周;观察两组患者谷丙转氨酶(ALT)、HBeAg、HBV-DNA水平和药物不良反应。结果两组患者经治后ALT水平均较治疗前明显下降(P3、临床症状,长期服用不良反应较小,安全性高。关键词:恩替卡韦;阿德福韦;慢性乙型肝炎病毒;感染;临床疗效中图分类号:R978.1文献标识码:A文章编号:1005—4529(2014)16—3972—03ClinicalefficacyofentecavirintreatmentofpatientswithchronichepatitisBvirusinfectionsJIANGBo,LIZhong,ZHANGYu(PeopleSHospitalofKailiCityinGuizhouPrefectureofQiandongnanProvince,Kaili,4、Guizhou556000,Cina)Abstract:OBJECTIVEToexploretheclinicalefficacyandsafetyofentecavirintreatmentofthepatientswithchronichepatitisBvirusinfectionsSOastoprovideguidanceforclinicaltreatment.METHODSAtotalof160patientswithchronichepatitisBwhoweretreatedinthehospitalfromJan2011tOJun20125、wereenrolledinthestudyandrandomlydividedintothecontrolgroupandtheobservationgroup,with80casesineach;theobserva—tiongroupwastreatedwithoraladministrationofdispersibletabletsofentecavir,0.5mgperday;thecontrolgroupwasgivenoraladministrationofadefovirdipivoxiltablet,10mgperday;thetrea6、tmentcourseofbothgroupswas48weeks;thelevelsofalanineaminotransferase(ALT),HBeAg,andHBV-DNAaswellastheinci—denceofadversereactionswereobservedandcomparedbetweenthetwogroups.RESULTSAscomparedwiththelevelofALTbeforethetreatment,itwassignificantlyreducedafterthetreatment(P7、gativerateofHBeAgwas33.3intheobservationgroup,30.2inthecontrolgroup,andthedifferencewasnotsignifi—cant.Afterthetreatment,thelevelofserumHBv_DNAwas(3.5±0.4)logl0copies/mlintheobservationgroup,significantlylowerthanthatofthecontrolgroup(P8、bitthereplicationandreproductiono
3、临床症状,长期服用不良反应较小,安全性高。关键词:恩替卡韦;阿德福韦;慢性乙型肝炎病毒;感染;临床疗效中图分类号:R978.1文献标识码:A文章编号:1005—4529(2014)16—3972—03ClinicalefficacyofentecavirintreatmentofpatientswithchronichepatitisBvirusinfectionsJIANGBo,LIZhong,ZHANGYu(PeopleSHospitalofKailiCityinGuizhouPrefectureofQiandongnanProvince,Kaili,
4、Guizhou556000,Cina)Abstract:OBJECTIVEToexploretheclinicalefficacyandsafetyofentecavirintreatmentofthepatientswithchronichepatitisBvirusinfectionsSOastoprovideguidanceforclinicaltreatment.METHODSAtotalof160patientswithchronichepatitisBwhoweretreatedinthehospitalfromJan2011tOJun2012
5、wereenrolledinthestudyandrandomlydividedintothecontrolgroupandtheobservationgroup,with80casesineach;theobserva—tiongroupwastreatedwithoraladministrationofdispersibletabletsofentecavir,0.5mgperday;thecontrolgroupwasgivenoraladministrationofadefovirdipivoxiltablet,10mgperday;thetrea
6、tmentcourseofbothgroupswas48weeks;thelevelsofalanineaminotransferase(ALT),HBeAg,andHBV-DNAaswellastheinci—denceofadversereactionswereobservedandcomparedbetweenthetwogroups.RESULTSAscomparedwiththelevelofALTbeforethetreatment,itwassignificantlyreducedafterthetreatment(P7、gativerateofHBeAgwas33.3intheobservationgroup,30.2inthecontrolgroup,andthedifferencewasnotsignifi—cant.Afterthetreatment,thelevelofserumHBv_DNAwas(3.5±0.4)logl0copies/mlintheobservationgroup,significantlylowerthanthatofthecontrolgroup(P8、bitthereplicationandreproductiono
7、gativerateofHBeAgwas33.3intheobservationgroup,30.2inthecontrolgroup,andthedifferencewasnotsignifi—cant.Afterthetreatment,thelevelofserumHBv_DNAwas(3.5±0.4)logl0copies/mlintheobservationgroup,significantlylowerthanthatofthecontrolgroup(P8、bitthereplicationandreproductiono
8、bitthereplicationandreproductiono
此文档下载收益归作者所有